Transcend Capital Advisors LLC Raises Holdings in Sanofi (NASDAQ:SNY)

Transcend Capital Advisors LLC lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 5.7% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 5,730 shares of the company’s stock after acquiring an additional 307 shares during the period. Transcend Capital Advisors LLC’s holdings in Sanofi were worth $285,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of SNY. Morgan Stanley boosted its holdings in Sanofi by 4.6% in the third quarter. Morgan Stanley now owns 7,322,806 shares of the company’s stock valued at $392,796,000 after purchasing an additional 323,968 shares during the last quarter. Envestnet Asset Management Inc. grew its position in Sanofi by 29.8% during the 3rd quarter. Envestnet Asset Management Inc. now owns 2,838,903 shares of the company’s stock worth $152,279,000 after purchasing an additional 651,756 shares during the period. Natixis Advisors L.P. grew its position in Sanofi by 15.9% during the 3rd quarter. Natixis Advisors L.P. now owns 2,528,289 shares of the company’s stock worth $135,618,000 after purchasing an additional 346,563 shares during the period. Raymond James & Associates grew its position in Sanofi by 1.5% during the 3rd quarter. Raymond James & Associates now owns 2,096,142 shares of the company’s stock worth $112,437,000 after purchasing an additional 31,773 shares during the period. Finally, American Century Companies Inc. grew its position in Sanofi by 1.0% during the 3rd quarter. American Century Companies Inc. now owns 1,472,190 shares of the company’s stock worth $78,968,000 after purchasing an additional 15,154 shares during the period. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on SNY shares. Morgan Stanley started coverage on Sanofi in a research report on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 price target on the stock. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 27th. Finally, TheStreet downgraded Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $55.00.

Sanofi Trading Up 0.3 %

SNY stock opened at $49.23 on Wednesday. The company’s 50-day simple moving average is $47.82 and its 200-day simple moving average is $48.25. The company has a quick ratio of 0.87, a current ratio of 1.27 and a debt-to-equity ratio of 0.19. Sanofi has a 52-week low of $42.63 and a 52-week high of $55.93. The firm has a market cap of $124.53 billion, a P/E ratio of 24.74, a PEG ratio of 1.37 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by ($0.05). Sanofi had a return on equity of 19.69% and a net margin of 10.52%. The firm had revenue of $11.76 billion for the quarter, compared to analysts’ expectations of $13.02 billion. As a group, equities analysts forecast that Sanofi will post 4.11 EPS for the current fiscal year.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be paid a $1.478 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This is a positive change from Sanofi’s previous annual dividend of $1.38. This represents a yield of 2.98%. Sanofi’s dividend payout ratio (DPR) is currently 69.35%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.